User profiles for Roy Alcalay

Roy Alcalay

Chief, Division of Movement Disorders, Tel Aviv Soursky Medical Center; Associate …
Verified email at columbia.edu
Cited by 13446

The neuropathology of genetic Parkinson's disease

M Poulopoulos, OA Levy, RN Alcalay - Movement Disorders, 2012 - Wiley Online Library
Pathological data from autopsies genotyped for Parkinson's disease (PD)‐related mutations
in alpha‐synuclein, Parkin, PINK1, DJ1, LRRK2, and glucocerebrosidase have …

T cells from patients with Parkinson's disease recognize α-synuclein peptides

D Sulzer, RN Alcalay, F Garretti, L Cote, E Kanter… - Nature, 2017 - nature.com
Genetic studies have shown the association of Parkinson’s disease with alleles of the major
histocompatibility complex 1 , 2 , 3 . Here we show that a defined set of peptides that are …

Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations

RN Alcalay, OA Levy, CH Waters, S Fahn, B Ford… - Brain, 2015 - academic.oup.com
Glucocerebrosidase (GBA) mutations have been associated with Parkinson’s disease in
numerous studies. However, it is unknown whether the increased risk of Parkinson’s disease in …

[HTML][HTML] Impact of the COVID‐19 pandemic on Parkinson's disease and movement disorders

…, C Colosimo, HL Chiang, RN Alcalay… - Movement disorders …, 2020 - ncbi.nlm.nih.gov
Human coronaviruses have classically caused mild respiratory infections. Two previous
outbreaks caused by newly identified coronaviruses, SARS-CoV in 2002 and MERS-CoV in …

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

…, A Aitkulova, V Akhmetzhanov, RN Alcalay… - The Lancet …, 2019 - thelancet.com
Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

…, Y Ma, PA Urenia, H Nguyen, RN Alcalay… - The Lancet …, 2023 - thelancet.com
Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease

…, JQ Trojanowski, HI Hurtig, RN Alcalay… - JAMA …, 2015 - jamanetwork.com
… Dr Alcalay receives research support from the NIH (K02 NS080915), Parkinson’s Disease
Foundation (PDF), Smart Foundation, and MJFF. Dr Marder receives research support from …

Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature

SA Schneider, RN Alcalay - Movement Disorders, 2017 - Wiley Online Library
Clinical–pathological studies remain the gold‐standard for the diagnosis of Parkinson's disease
(PD). However, mounting data from genetic PD autopsies challenge the diagnosis of PD …

The association between Mediterranean diet adherence and Parkinson's disease

RN Alcalay, Y Gu, H Mejia‐Santana, L Cote… - Movement …, 2012 - Wiley Online Library
Background: Recent studies have demonstrated an association between a Mediterranean‐type
diet and Alzheimer's risk. We assessed the association between Mediterranean‐type …

Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy

…, MK Pan, OJ Lieberman, SJ Hutten, RN Alcalay… - Science …, 2022 - science.org
The most common genetic risk factors for Parkinson’s disease (PD) are a set of heterozygous
mutant (MT) alleles of the GBA1 gene that encodes β-glucocerebrosidase (GCase), an …